All Stories

  1. Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  2. The silent exclusion: rethinking eligibility and generalizability in clinical trials
  3. Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments
  4. Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial
  5. Beyond survival: improving lung cancer rehabilitation through standardised outcomes
  6. Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019
  7. Decoding community-acquired pneumonia: a systematic review and analysis of diagnostic criteria and definitions used in clinical trials
  8. Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  9. Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
  10. Predictors of treatment REsponse to inhaled corticosteroids (ICS) in Chronic Obstructive pulmonary disease: randomised controlled trials individual participant Data re-Evaluation–protocol of the ICS-RECODE individual participant data meta-analysis
  11. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  12. ERS Congress 2024: highlights from the Airway Diseases Assembly
  13. Prevalence of Respiratory Viruses in Stable and Acute Asthma: A Systematic Review and Meta-Analysis
  14. Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma
  15. Rethinking Blood Eosinophils for Assessing Inhaled Corticosteroids Response in COPD
  16. Steroids in severe community-acquired pneumonia
  17. GRADE guidance 39: using GRADE-ADOLOPMENT to adopt, adapt or create contextualized recommendations from source guidelines and evidence syntheses
  18. Effect of low climate impact vs. high climate impact inhalers for patients with asthma and COPD-a nationwide cohort analysis
  19. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
  20. Inhaled Corticosteroids Particle Size and Risk of Hospitalization Due to Exacerbations and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study
  21. European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
  22. AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries
  23. Unravelling the complexity of ventilator-associated pneumonia: a systematic methodological literature review of diagnostic criteria and definitions used in clinical research
  24. The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019
  25. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  26. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a syst...
  27. Burden of disease scenarios for 204 countries
  28. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  29. Current options in the management of tree nut allergy: A systematic review and narrative synthesis
  30. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO
  31. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
  32. Immunomodulatory drugs in sepsis: a systematic review and meta‐analysis
  33. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
  34. Global Health Trends 1950–2021: Impact of COVID-19 on Mortality and Population Growth
  35. Reply to “The use of basophil activation tests (BATs) in the diagnosis of penicillin allergy”
  36. Performance Characteristics of Basophil Activation Tests for Diagnosing Penicillin Allergy: A Meta-Analysis
  37. Prognostic factors for mortality, ICU, MIS-C and hospital admission due to SARS-CoV-2 in paediatric patients: A systematic review and meta-analysis
  38. Inhaledversussystemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis
  39. The Fagerström Test for Nicotine Dependence, as a prognostic factor, in current smokers with and without COPD: A cross-sectional study in northern Greece
  40. Covariates in population pharmacokinetic studies of critically ill adults receiving β-lactam antimicrobials: a systematic review and narrative synthesis
  41. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments
  42. ERS International Congress 2023: highlights from the Airway Diseases Assembly
  43. Prevalence and clinical implications of respiratory viruses in asthma during stable disease state and acute attacks: Protocol for a meta-analysis
  44. Promising treatment biomarkers in asthma
  45. Rethinking Blood Eosinophils for Assessing ICS Response in COPD: A Post-Hoc Analysis from FLAME
  46. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
  47. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  48. Impact of self-reported environmental mould exposure on COPD outcomes
  49. Population pharmacokinetics critically ill beta lactam (ClinicalTrials.gov).
  50. Population pharmacokinetics critically ill beta lactam (Cochrane, CENTRAL).
  51. Population pharmacokinetics critically ill beta lactam (Embase, Ovid).
  52. Population pharmacokinetics critically ill beta lactam (MEDLINE (R) All, Ovid).
  53. Population pharmacokinetics critically ill beta lactam (Web of Science).
  54. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
  55. Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition
  56. Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022
  57. Current and Optimal Practices in Childhood Asthma Monitoring Among Multiple International Stakeholders
  58. ERS International Congress 2022: highlights from the Airway Diseases Assembly
  59. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  60. Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials
  61. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID
  62. Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus pneumoniae Infection. A Multiregional Epidemiological Study
  63. Impact of triple therapy on mortality in COPD
  64. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis
  65. The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease
  66. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study
  67. How to peer review: practical advice for early career researchers
  68. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
  69. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis
  70. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions
  71. West Nile Disease Symptoms and Comorbidities: A Systematic Review and Analysis of Cases
  72. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  73. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  74. Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
  75. Peripheral neuropathy: A neglected cause of disability in COPD – A narrative review
  76. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019
  77. Presence of antiphospholipid antibodies is associated with increased implantation failure following in vitro fertilization technique and embryo transfer: A systematic review and meta-analysis
  78. Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
  79. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
  80. Transmission of SARS-CoV-2 in educational settings in 2020: a review
  81. Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe
  82. Inspiring stories: the impact that being part of ERS activities can have on a professional career
  83. Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019
  84. Outcomes assessed in therapeutic randomized controlled trials in hospitalized patients with COVID-19: is the meta Core Outcome Set (meta-COS) adopted?
  85. Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms
  86. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  87. Intermittent prophylactic antibiotics for bronchiectasis
  88. Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study
  89. Management of COVID-19-Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation
  90. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  91. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
  92. Chronic obstructive pulmonary disease and COVID-19: interrelationships
  93. The role of educational settings in the transmission chain of SARS-CoV-2 in 2020: a systematic review
  94. ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
  95. Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19
  96. ERS/EAACI statement on adherence to international adult asthma guidelines
  97. Stigma: an unmet public health priority in COPD
  98. Automated lung sound analysis using the LungPass platform: A sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19
  99. Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank
  100. Corticosteroid Resistance in Smokers—A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial
  101. ERS clinical practice guidelines on treatment of sarcoidosis
  102. Screening, Diagnostic and Prognostic Tests for COVID-19: A Comprehensive Review
  103. The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea
  104. Multidimensional indices in the assessment of chronic obstructive pulmonary disease
  105. Alterations in T and B cell function persist in convalescent COVID-19 patients
  106. Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials
  107. Triglyceride-Glucose Index in Non-Diabetic, Non-Obese Patients with Obstructive Sleep Apnoea
  108. Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort
  109. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
  110. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey
  111. P190 Systematic survey of reported outcomes in ventilator associated pneumonia randomised controlled trials
  112. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis
  113. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making
  114. Developing trustworthy recommendations as part of an urgent response (1–2 weeks): a GRADE concept paper
  115. Polymorphisms of the Glucocorticoid Receptor Gene and Adrenal Suppression in Patients with Chronic Obstructive Pulmonary Disease Treated with Glucocorticoids for Acute Exacerbations
  116. Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review
  117. Current developments and future directions in COPD
  118. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes
  119. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort
  120. Outcomes evaluated in controlled clinical trials on the management of COVID-19: A methodological systematic review
  121. Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 convalescence
  122. Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial
  123. Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19
  124. Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden
  125. Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease
  126. Severity-stratified and longitudinal analysis of VWF/ADAMTS13 imbalance, altered fibrin crosslinking and inhibition of fibrinolysis as contributors to COVID-19 coagulopathy
  127. Comparison of the Level of Awareness about the Transmission of Echinococcosis and Toxocariasis between Pet Owners and Non-Pet Owners in Greece
  128. Problems arising from the conduct of multiple trials evaluating the same interventions for COVID-19
  129. The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision
  130. Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol
  131. Longitudinal immune profiling reveals distinct features of COVID-19 pathogenesis
  132. Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
  133. Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol
  134. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits
  135. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
  136. The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma
  137. ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly
  138. Corrigendum to: Transfusion-Transmitted Malaria: A Systematic Review and Meta-Analysis
  139. Long-Lasting Alterations in T and B Cell Function in Convalescent COVID-19 Patients
  140. A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
  141. Laboratory Cross-Contamination of Mycobacterium tuberculosis: A Systematic Review and Meta-analysis
  142. Transfusion-Transmitted Malaria: A Systematic Review and Meta-analysis
  143. How do clinical trials on COPD exacerbations evaluate the effect treatments have on patients?
  144. Was the implementation strategy of the ProACT trial adequately proactive?
  145. Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration
  146. Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services
  147. Research highlights from the 2018 European Respiratory Society International Congress: airway disease
  148. Intermittent prophylactic antibiotics for bronchiectasis
  149. What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs [Erratum]
  150. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis
  151. Biomarkers to guide antibiotic therapy for COPD exacerbations
  152. Capsule Commentary on Ashburner et al., Electronic Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation: a Randomized Controlled Trial
  153. What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs
  154. EARLY versus MILD Chronic Obstructive Pulmonary Disease (COPD)
  155. Continuous versus intermittent antibiotics for bronchiectasis
  156. COPD and Stroke
  157. The emerging Chinese COPD epidemic
  158. Capsule Commentary on Bremmer et. al., Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations
  159. Research highlights from the 2017 ERS International Congress: airway diseases in focus
  160. Early Career Members at the ERS International Congress 2017: highlights from the Assemblies
  161. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
  162. Airways diseases: insights from the European Respiratory Society Annual Congress 2017
  163. ERS Early Career Members meet EAACI Junior Members: the launch of a strong, fruitful collaboration
  164. Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis
  165. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence
  166. Interventions to improve inhaler technique and adherence to inhaled corticosteroids in children with asthma
  167. Opportunities for early career members
  168. Relationship of Allergy with Asthma: There Are More Than the Allergy “Eggs” in the Asthma “Basket”
  169. Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis
  170. Interventions to improve inhaler technique for people with asthma
  171. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis
  172. Early Career Members at the ERS International Congress London 2016
  173. How to keep good clinical records
  174. Prevalence and burden of comorbidities in COPD
  175. Valvular-CHADS-VASc as a safer alternative to CHADS-VASc score
  176. Serum procalcitonin can guide antibiotic administration for respiratory tract infections in primary care
  177. Obstructive Sleep Apnea and Hypertension: A Bidirectional Causal Relation
  178. Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnoea
  179. The risk of tachyarrhythmias in patients with moderate-to-severe chronic kidney disease receiving tiotropium bromide
  180. Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations
  181. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent?
  182. COPD Phenotypes and Biomarkers: Introducing Personalised Medicine
  183. Management of Stable COPD: An Update
  184. Editorial from Guest Editor (Thematic Issue: Current Approach to COPD Management: Setting a Model in Medical Therapeutics)
  185. Tiotropium HandiHaler Improves the Survival of Patients with COPD: A Systematic Review and Meta-Analysis
  186. Drugs that Act on the Respiratory Tract
  187. Expression of Bmi1, FoxF1, Nanog, and γ-Catenin in Relation to Hedgehog Signaling Pathway in Human Non-small-Cell Lung Cancer
  188. Tiotropium Inhaler Devices: Seeking Convenience When Mortality Is at Stake?
  189. Impact of long‐term treatment with low‐dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: Aggravating or beneficial?
  190. Chronic bronchitis: an objective diagnosis of exclusion